Figitumumab
- Generic Name
- Figitumumab
- Drug Type
- Biotech
- CAS Number
- 943453-46-1
- Unique Ingredient Identifier
- VE267FC2UB
- Background
Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
- Conditions
- Advanced Non-Hematologic Malignancies
- Interventions
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT01653158
- Locations
- 🇬🇧
Pfizer Investigational Site, Sutton, Surrey, United Kingdom
CP-751,871 Treatment For Patients With Multiple Myeloma
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT01536145
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT00977561
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
- Conditions
- Colorectal NeoplasmsLung NeoplasmsBreast NeoplasmsProstatic NeoplasmsSarcoma
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00976508
- Locations
- 🇩🇪
Pfizer Investigational Site, Muenster, Germany
RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Suzanne George, MD
- Target Recruit Count
- 21
- Registration Number
- NCT00927966
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00907504
A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Target Recruit Count
- 37
- Registration Number
- NCT00872404
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
🇧🇪Cliniques universitaires Mont-Godinne, Yvoir, Namur, Belgium
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
- Conditions
- Advanced CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00729833
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00678626
Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00560573
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.